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Summary
Transforming growth factor-b (TGF-b) has been impli-
cated in the control of differentiation and proliferation
of multiple cell types. However, a role for TGF-b in the
control of immune homeostasis is not fully under-
stood because of its pleiotropic action. Here we report
that complete ablation of the TGF-b signaling in T cells
engendered aggressive early-onset, multiorgan, auto-
immune-associated lesions with 100% mortality. Pe-
ripheral CD4+ and CD8+ T cells with TGF-b-receptor II
(TGF-bRII) deficiency activated cytolytic and T helper 1
(Th1) differentiation program in a cell-intrinsic T cell
receptor (TCR)-specific fashion. Furthermore, TGF-
bRII deficiency blocked the development of canonical
CD1d-restricted NKT cells. Instead, it facilitated gener-
ation of a highly pathogenic T cell subset exhibiting
multiple hallmarks of NK cells and sharply elevated
amounts of FasL, perforin, granzymes, and inter-
feron-g. Thus, TGF-b signaling in peripheral T cells is
crucial in restraining TCR activation-dependent Th1,
cytotoxic, and NK cell-like differentiation program
which, when left unchecked, leads to rapidly progress-
ing fatal autoimmunity.
Introduction
Transforming growth factor-b (TGF-b) family cytokines
TGF-b1, TGF-b2, and TGF-b3 serve as positive and neg-
ative regulators of differentiation and proliferative pro-
grams in numerous cell types (Letterio and Roberts,
1998). Upon binding to their receptors, all three TGF-b
isoforms induce kinase activity of the intracellular do-
main of the common TGF-bRII subunit, which in turn
phosphorylates the kinase domain of the TGF-bRI sub-
unit. Upon another round of catalytic phosphorylation,
the latter facilitates Smad-dependent regulation of gene
transcription and activates several other signaling path-
ways in a Smad-independent manner (Derynck and
Zhang, 2003).
Within the immune system, TGF-b2 and TGF-b3 are
not expressed at a substantial amount, whereas TGF-
b1 is prevalent and plays a major regulatory role in the
immune system, controlling activation and effector func-
tion of both lymphoid and nonlymphoid cells (Letterio
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mediated control of immune homeostasis was revealed
by investigation of germline ablation of Tgfb1 gene ex-
pression. Mice with a targeted disruption of Tgfb1 gene
exhibit embryonic lethality with a variable degree of pen-
etrance depending upon particular genetic background
resulting in developmental defects in nonlymphoid or-
gans. TGF-b1-deficient mice that are born develop se-
vere autoimmune multiorgan pathology including severe
myocarditis, lymphadenopathy, and vasculitis and die at
3–4 weeks of age (Kulkarni et al., 1993; Shull et al., 1992).
However, specific cellular mechanisms of the autoim-
mune disease observed in these mice have been difficult
to decipher because of pleiotropic effects of TGF-b sig-
naling on multiple tissues and the broad distribution of
TGF-b receptors both within and outside the immune
system. In order to address a role of TGF-b signaling in
T cells, several groups have generated transgenic mice
expressing a dominant-negative form of TGF-bRII lack-
ing the kinase domain (DN-TGF-bRII) under a T cell-spe-
cific promoter (Gorelik and Flavell, 2000; Lucas et al.,
2000). The latter mice develop autoimmune pathology,
albeit markedly milder, and with a substantially delayed
onset at 4–6 months of age, as compared to aggressive
autoimmunity commencing during the third week of life
ofTgfb12/2mice. The most likely explanation for this dis-
crepancy is that inTgfb12/2mice, an impairment in either
development or homeostasis of nonlymphoid tissues
provokes, directs, or greatly accelerates exuberant T
cell reactivity left unchecked in the absence of TGF-b re-
ceptor signaling. The previously reported role for TGF-b1
in the regulation of differentiation and homeostasis of
cardiomyocytes, pancreatic bcells, and blood vessel en-
dothelium is fully consistent with this idea (Wang et al.,
2005; Smart et al., 2006; Larsson et al., 2001). Alterna-
tively, it is possible that expression of DN-TGF-bRII
transgene does not completely extinguish TGF-b signal-
ing in T cells and therefore allows for a variable degree of
control of T cell responsiveness depending on the local
concentration of TGF-b and the extent of T cell stimula-
tion. Furthermore, it is not clear whether TGF-b signaling
deficiency affects some aspects of T cell development in
the thymus, leaving open a possibility that thymocyte
maturation might be altered to a different degree in
Tgfb12/2 and DN-TGF-bRIITg mice.
In order to definitively address a role for TGF-b signal-
ing in control of peripheral T cell tolerance and homeo-
stasis, we have generated mice with the abT cell-spe-
cific deletion of a conditional TGF-bRII allele. Because
TGF-bRI alone in the presence of TGF-b ligands does
not induce any measurable signaling (Massague et al.,
1992), this strategy allows for complete abrogation of
the TGF-b signaling in abT cells in these mice. Unexpect-
edly, Tgfbr2fl/fl x CD4-Cre mice developed fatal autoim-
mune pathology that is arguably even more aggressive
than that observed in Tgfb12/2 mice and die by 3 weeks
of age. The pathology is mediated by activated CD8+
and CD4+ T cells, which express high amounts of FasL
and IFN-g in the absence of TGF-b signaling. These T
cells do not seem to arise from a spontaneous activation
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442Figure 1. Early-Onset Multiorgan Autoimmune Pathology in Mice with the T Cell-Specific Ablation of TGF-b Signaling
(A) Flow cytometric analysis of TGF-bRII expression by splenic T cells, B cells, dendritic cells (DC), and macrophages isolated from 16- to 18-day-
old Tgfbr2fl/fl x CD4-Cre (KO) and Tgfbr2fl/WTx CD4-Cre littermate control (Control) mice.
(B) Representative micrographs of H&E-stained tissue sections of indicated organs isolated from 16- to 18-day-old KO and Lit control animals
(3100). The results are representative of analysis of more than 10 animals per group. Histologic lesions include lymphocytic cholangiohepatitis
(liver), insulitis (pancreatic islet), interstitial myositis (skeletal muscle and heart), and chronic-active dermatitis (skin).of T cells independently of their TCR specificity but most
likely represent activated peripheral self-reactive cells.
The latter cells, present within the normal peripheral
T cell repertoire, are kept in check in wild-type mice
but manifest their pathogenic potential in the absence
of TGF-b signaling even when wild-type regulatory T
cells are present. Thymic development of conventional
CD1d-restricted NKT cells was blocked in Tgfbr2fl/fl x
CD4-Cre mice. However, a substantial proportion of
CD8+ T cells as well as CD4+ T cells in these mice ac-
quired multiple molecular aspects characteristic of NK
cell differentiation program and exhibited high patho-
genic potential. Overall, our results reveal that TGF-b sig-
naling in T cells is a distinct, vitally important mechanism
of immune tolerance of no lesser significance than
CTLA-4- and Foxp3-mediated mechanisms.
Results
TGF-b Signaling in T Cells Controls Autoimmune
Disease Development
To selectively extinguish TGF-b signaling in ab TCR T
cells, mice expressing Cre recombinase under the con-
trol of a CD4 promoter (CD4-Cre) (Lee et al., 2001) were
bred to mice harboring a conditional Tgfbr2 allele(Leveen et al., 2002). Because CD4-Cre transgene is
efficiently expressed at the double-positive (DP) stage
of thymocyte development, in Tgfbr2fl/fl CD4-Cre mice,
both CD4+ and CD8+ T cells were deficient in TGF-
bRII, whereas its expression by other cell types was un-
affected and was similar to that of littermate control
mice (Figure 1A). With a recombination reporter allele,
we did not detect substantial CD4-Cre deletion in any
cell types except ab T cells (Wolfer et al., 2001; J. Fonte-
not and A.Y.R, unpublished observations). In contrast to
slowly developing lung and gastrointestinal tract inflam-
mation previously reported in DN-TGF-bRII transgenic
mice, in the second and third week of life, Tgfbr2fl/fl x
CD4-Cre mice developed a highly aggressive, early-
onset autoimmune disease characterized by marked
lymphadenopathy, diffuse hepatocellular lipidosis with
lymphocytic cholangiohepatitis, and lymphocytic myo-
sitis involving both the myocardium and skeletal mus-
cles. Inflammation of the heart was accompanied by
grossly obvious cardiac hypertrophy. Additional histo-
logic changes included chronic-active lymphocytic der-
matitis with acanthosis and hyperkeratosis and a similar
inflammatory and proliferative change involving the
squamous portion of the stomach (forestomach), con-
sistent with that seen in mice with graft-versus-host
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443disease (GVHD). There was also obvious lymphocytic
insulitis albeit without frank diabetes demonstrable by
blood glucose tests (Figure 1B; see Figure S1 in the
Supplemental Data available online; data not shown).
Finally, in the brain and spinal cord, we observed wide-
spread lymphocytic perivasculitis and meningitis (data
not shown). These manifestations were similar to, if not
more severe than, those reported in TGF-b1-deficient
mice.
In addition to severe and widespread histologic le-
sions, Western blot analysis of sera from Tgfbr2fl/fl x
CD4-Cre mice demonstrated the presence of IgG auto-
antibodies reactive with a number of self-proteins pres-
ent in detergent-solubilized whole-tissue extracts iso-
lated from heart, skeletal muscle, and skin. In contrast,
relatively low amounts of autoreactive IgG antibodies
were found in serum from littermate control animals
(Figure S2A). These results are in agreement with previ-
ously reported findings of serum autoantibodies in TGF-
b1-deficient mice and in DN-TGF-bRII transgenic mice
(Yaswen et al., 1996; Gorelik and Flavell, 2000).
Between 2 and 3 weeks of age, Tgfbr2fl/fl x CD4-Cre
mice exhibited profound weight loss due to a progres-
sive wasting disease, likely resulting from rampant
myocarditis and liver damage, and died at 3 weeks of
age (data not shown). Thus, TGF-b signaling in T cells
is crucial for the control of autoimmunity and its failure
results in highly aggressive, early-onset multiorgan
autoimmune-associated lesions.
Peripheral T Cell Activation
in Tgfbr2fl/fl x CD4-Cre Mice
To better understand cellular mechanisms of the ob-
served autoimmune disease, we next examined thymic
and peripheral T cell subsets in young Tgfbr2fl/fl x
CD4-Cre mice prior to the development of overt clinical
symptoms. At 12 days of age, thymus cellularity and the
size of double-negative (DN), DP, as well as both CD4
and CD8 single-positive (SP) thymocyte subsets were
indistinguishable between mutant and littermate control
animals. Furthermore, abTCR expression and expres-
sion of thymocyte maturation and activation markers
such as CD24, CD69, and CD5 in DP and SP thymocytes
were not affected by TGF-bRII deficiency in abT cells
(Figure 2A; data not shown). In contrast to unaltered
thymocyte development, a 2- to 3-fold increase in size
of peripheral CD4+ and CD8+ T cell subsets was ob-
served in 12-day-old mutant mice with a further increase
in numbers of splenic and lymph node T cells by day 17
as compared to littermate controls (Figure 2B). At this
age, spleens of mutant mice also contained substan-
tially increased numbers of B cells (data not shown).
By day 21, numbers of T cells were diminished in sec-
ondary lymphoid organs likely due to migration to non-
lymphoid tissues, increased apoptosis of activated
rapidly dividing TGF-bRII-deficient T cells, or terminal
wasting disease (data not shown).
Peripheral T cell expansion was associated with a pro-
nounced upregulation of T cell activation markers CD69
and CD44, downregulation of CD62L, and an increase
in expression of adhesion molecules such as CD54,
CD11a, and CD11b (Figure 2C). Furthermore, activated
CD4+ T cells in these mice exhibit somewhat increased
CD40L expression, which might contribute to a breakin B cell tolerance in these mice (data not shown).
Consistently with these findings, analysis of serum Ig
isotypes demonstrated substantially elevated concen-
trations of IgG2a and IgA (Figure S2B).
Uncontrolled Activation of T Cells Lacking
TGF-bRII Is TCR Specificity Dependent
There are several explanations for the massive activa-
tion of T cells in the absence of TGF-b signaling. First,
based on the analysis of T cell activation markers in
DN-TGF-bRII mice, it was suggested that attenuated
TGF-b signaling in T cells results in their spontaneous
activation (Gorelik and Flavell, 2000). Alternatively, it is
possible that self-reactive TGF-bRII-deficient T cells
preferentially expand and mediate autoimmune pathol-
ogy. An additional factor potentially contributing to T
cell activation in Tgfbr2fl/fl x CD4-Cre mice is the inability
of regulatory T (Treg) cells to control TGF-bRII-deficient
effector T cells in a setting of a specific tissue inflamma-
tion (Peng et al., 2004; Fahlen et al., 2005). However, an
important question remains as to whether aggressive
systemic autoimmunity associated with complete TGF-
b signaling deficiency in T cells can be controlled by
Treg cells. Further, we have found diminished numbers
of peripheral Foxp3+ Treg cells in TGF-b-deficient, but
not in DN-TGF-bRII transgenic, mice (Marie et al.,
2005; data not shown). Thus, these contradicting data
allow for several alternative interpretations of cellular
mechanisms of autoimmunity unleashed by TGF-b sig-
naling deficiency. Studies described in this section
examine all of the aforementioned possibilities.
To test whether activation of T cells in the absence of
TGF-b signaling is spontaneous or is dependent upon
certain TCR specificity, we bred Tgfbr2fl/fl x CD4-Cre
mice onto TEa TCR transgenic mice. In the latter mice,
a transgene (tg) encoding Vb6+Va2+ TCR TEa specific
for Ea52-68 peptide bound to I-Ab is expressed by
more than 90% of peripheral T cells, whereas a small
number of T cells express endogenously rearranged
TCR genes. This peptide is derived from Ea chain lack-
ing in B6 (H-2b) mice; therefore, this peptide serves
as a ‘‘foreign’’ ligand for transgenic TEa TCR. Autoim-
mune disease as manifested by lymphoadenopathy
was insignificant in 19- to 21-day-old TEa mice due to
a drastically skewed TCR repertoire. Analysis of activa-
tion markers on TCR tg (Vb6+Va2+)- and endogenous
TCR (Vb62Va22)-expressing CD4+ T cells showed that
only cells expressing endogenous TCR were activated
based on the expression pattern of CD62L and CD44
(Figure 2D). These results strongly support TCR speci-
ficity-dependent activation of TGF-bRII-deficient T cells
likely occurring upon self-antigen recognition.
To assess development of regulatory Foxp3+ T cells in
mice with the T cell-specific ablation of TGF-bRII signal-
ing, we bred recently generated Foxp3gfp allele onto
Tgfbr2fl/fl x CD4-Cre mice. Flow cytometric analysis of
Foxp3gfp x Tgfbr2fl/fl x CD4-Cre and littermate control
Foxp3gfp x Tgfbr2fl/wt x CD4-Cre mice showed compara-
ble size of Foxp3-expressing thymocyte subsets and
comparable Foxp3 expression on a per cell basis (Fig-
ure 2E). However, very few Foxp3+ T cells were found
in the lymph nodes and spleen of Foxp3gfp x Tgfbr2fl/fl x
CD4-Cre mice. These data demonstrate that TGF-b sig-
naling does not play a nonredundant role in thymic
Immunity
444Figure 2. TGF-bRII Deficiency Leads to TCR Specificity-Dependent Activation of Peripheral T Cells Resistant to Foxp3+ Treg Cell-Mediated
Control
(A) Flow cytometric analysis of CD4 and CD8 expression on thymocytes or splenocytes from 12-day-old Tgfbr2fl/fl x CD4-Cre mice (KO) or
Tgfbr2fl/WT x CD4-Cre littermate controls (Control).
(B) Absolute numbers of splenic CD4+ and CD8+ T cells in KO and control mice of indicated ages (mean6 SD; n = 10 analyzed in four independent
experiments).
(C) Flow cytometric analysis of expression of T cell activation markers by splenic CD4+ or CD8+ T cells isolated from 16- to 18-day-old KO or
control mice. These results are representative of four independent experiments with total of 10 mice per group analyzed.
(D) Flow cytometric analysis of activation phenotype of CD4+ T cells expressing endogenous (Vb62Va22) or transgene-encoded (Vb6+Va2+) TEa
TCR in TEa tg x Tgfbr2fl/fl x CD4-Cre mice. These results are representative of two independent experiments with total 3–4 animals per group
analyzed.
(E) Flow cytometric analysis of Foxp3, CD25, and GITR expression in thymic and splenic Treg subsets in 17-day-old Tgfbr2fl/fl x CD4-Cre x
Foxp3gfp mice (KO) or their littermate Tgfbr2fl/WT x CD4-Cre x Foxp3gfp controls (Control). The results are representative of five independent
experiments with total 15 animals per group.
(F) Flow cytometric analysis of activation phenotype of T cells in mixed bone marrow chimeras. T-depleted BM cells from Tgfbr2fl/fl x CD4-Cre
mice (KO, red), TEa TCR transgenic mice (TEa, green), and Thy-1.1+ congenic wild-type animals (wt, blue) were mixed at 1:1:1 ratio (106 cells
each) and transferred into irradiated Rag12/2 recipient. Expression of T cell activation markers CD62L and CD44 staining on either CD4+ or
CD8+ T cells was assessed 4.5–5 weeks after BM transfer. The results are representative of two independent experiments with four recipient
animals analyzed.
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445development of regulatory T cells, but is required to
maintain Foxp3-expressing Treg cell subset in the sec-
ondary lymphoid organs. These results suggest a possi-
bility that greatly diminished numbers of regulatory
Foxp3+ T cells can account for activation of self-reactive
TGF-bRII-deficient T cells in Tgfßr2fl/fl x CD4-Cre mice.
To examine this possibility, we tested whether TGF-
bRII-deficient T cells can be kept in check by regulatory
TGF-bRII-sufficient T cells by performing mixed bone
marrow (BM) transfers into sublethally irradiated (600
rads) RAG-deficient recipients. This series of experi-
ments also tested whether activation of self-reactive
TGF-bRII-deficient T cells can induce a bystander acti-
vation of T cells specific for a foreign antigen. First,
Ly9.1-expressing Tgfbr2fl/fl x CD4-Cre BM cells were
transferred intoRag12/2 recipients either alone or mixed
with the allelically marked wild-type BM cells at a 1:1 ra-
tio. All chimeric mice developed comparable lymphade-
nopathy and wasting disease and die by 6 weeks after
BM reconstitution despite the presence of essentially
normal numbers of Treg cells derived from wild-type
bone marrow in mixed bone marrow chimeras (w15%
CD4+ T cells; see Figure S2). In some transfer experi-
ments, Tgfbr2fl/fl x CD4-Cre BM was mixed with the
TGF-bRII-sufficient allelically marked B6 and TCR tg
TEa BM at 1:1:1 ratio and transferred into sublethally ir-
radiated Rag12/2 mice. In these experiments, TEa BM
was added as a source of easily identifiable T cells spe-
cific for a known foreign antigen. Analysis of CD62L and
CD44 expression revealed that only Tgfbr2Ifl/fl x CD4-
Cre BM-derived T cells showed activated phenotype
whereas TEa and congenic B6 BM-derived T cells did
not (Figure 2F). The latter finding indicates that wild-
type Treg cells are capable of keeping in check TGF-
bRII sufficient, but not TGF-bRII-deficient, T cells in
these chimeric mice. Thus, activation of TGF-b signal-
ing-deficient T cells is not prevented or even slowed
down by the presence of wild-type Treg cells. Overall,
these results suggest a cell-intrinsic role of TGF-bRII
deficiency in the activation of highly pathogenic self-
reactive T cells and indicate that a major reduction in
peripheral regulatory T cell compartment alone cannot
account for the aggressive pathology observed in
Tgfbr2fl/fl x CD4-Cre mice.
Canonical and Noncanonical NKT Cell
Differentiation in Tgfbr2fl/fl x CD4-Cre Mice
We next examined development of another major subset
of self-reactive T cells, CD1d-restricted NKT cells, in
Tgfbr2fl/fl x CD4-Cre mice by staining thymic and splenic
T cells with CD1d tetramers loaded with a galactosylcer-
amide (aGalCer-CD1d). Unexpectedly, we found a com-
plete absence ofaGalCer-CD1d-reactive NKT cells in the
thymus and in the spleen of Tgfbr2fl/fl x CD4-Cre mice
whereas normal proportions of NKT cells were present
in littermate control Tgfbr2fl/WT x CD4-Cre mice (Fig-
ure 3A). Thus, TGF-b signaling is critically required for
thymic development of NKT cells expressing canonical
semi-invariant CD1d-restricted TCR.
In contrast to the complete block in conventional NKT
cell development, we found a greatly expanded subset
of CD4+ and CD8+ T cells expressing NK1.1 in the spleen
and liver of mutant Tgfbr2fl/fl x CD4-Cre mice. Interest-
ingly, these NK1.1+ T cells expressed diverse abTCRinstead of canonical Va14+ TCR and did not bind
aGalCer-CD1d tetramers. It is also noteworthy that T
cells expressing CD8ab dimers account for more than
two thirds of NK1.1+ T cell subset in experimental ani-
mals (data not shown; Figures 3B–3D). In contrast,
aGalCer-CD1d2 NK1.1+CD4+ T cell subset in Tgfbr2fl/wt
x CD4-Cre littermate control mice is much smaller,
whereas NK1.1+CD8+ TCRab T cell subset was negligi-
ble (Figures 3B and 3D). Further flow cytometric charac-
terization of these aGalCer-CD1d-nonreactive NK1.1+
T cells revealed additional molecular features of NK
cells. We found that a sizable proportion of both
NK1.1+ CD4+ and NK1.1+ CD8+ T cells express a number
of surface receptors characteristic of NK cells including
DX5, NKG2A/C/E, NKG2D, and CD94. However, these
cells did not express marked amounts of CD16/CD32
(Figure 3E).
NK1.1+ T Cell Subset in Tgfbr2fl/fl x CD4-Cre
Mice Is Highly Pathogenic
Because we found substantially increased numbers of
noncanonic NK1.1+ T cells in Tgfbr2fl/fl x CD4-Cre mice
and these mice were afflicted by aggressive autoimmune
disease, we tested the ability of TGF-bRII-deficient
NK1.1+ and NK1.12 T cells to induce lesions upon their
adoptive transfer into lymphopenic Rag12/2 recipients.
5 weeks after transfer of Tgfbr2fl/fl x CD4-Cre NK1.1+ T
cells, recipient mice had large accumulations of lympho-
cytes and other inflammatory cells surrounding hepatic
blood vessels and bile ducts, had GVHD-like proliferative
gastritis of the forestomach, and displayed myositis
involving both skeletal and cardiac muscles (Figure 4).
In contrast, NK1.12 T cell transfers led to inflammation
in the liver but not in the heart, skeletal muscle, or stom-
ach. Notably, the limited histologic lesions in the liver
induced by NK1.12 T cells observed at 5 weeks after
transfer contrasted with those induced by NK1.1+ T cells.
In these experiments, T cells from Tgfbr2fl/wt x CD4-Cre
littermate control mice did not induce substantial lesions
in the liver or in other organs (Figure 4). At later time
points, mutant NK1.12 T cells induced more pathology
in recipient mice, suggesting that these cells are also
pathogenic albeit to a lesser degree than their NK1.1+
counterparts (data not shown). We also speculate that
TGF-bRII-deficient NK1.1+ T cells might survive exten-
sive cell division induced upon adoptive transfer into
lymphopenic hosts better as compared to their NK1.12
counterparts due to expression of inhibitory NK recep-
tors. Thus, NK1.1+ T cells developing in Tgfbr2fl/fl x
CD4-Cre mice likely represent the most potent patho-
genic T cell subset developing in these mice.
Acquisition of Cytolytic/Th1 Effector
Cell Differentiation Program by
TGF-bRII-Deficient T Cells
To better understand the basis for pathogenicity of
TGF-bRII-deficient NK1.1+ T cells, we performed gene
expression profiling of NK1.1+ and NK1.12 T cell subsets
from Tgfbr2fl/fl x CD4-Cre mice. We limited our analysis
to CD8+ T cell subsets because NK1.1+ CD8 T cells
made up w70% of total NK1.1+ T cells in Tgfbr2fl/fl x
CD4-Cre mice, and this T cell subset showed the great-
est numerical increase compared to littermate control
mice. Thus, in these experiments we used FACS-sorted
Immunity
446Figure 3. Lack of Canonic CD1d-Dependent NKT Cells and Enhanced Development of Noncanonic NK1.1+ CD8+ and CD4+ T Cells in Tgfbr2fl/fl x
CD4-Cre Mice
(A) Flow cytometric analysis of aGalCer-CD1d tetramer binding to TCRab+ CD4+ thymocytes and splenic CD4+ T cells from Tgfbr2fl/fl x CD4-Cre
(KO) or Tgfbr2fl/WT x CD4-Cre littermate control (Control) mice.
(B) Flow cytometric analysis of NK1.1 and TCRb expression by splenic and hepatic lymphocytes in Tgfbr2fl/fl x CD4-Cre mice (KO) or littermate
control Tgfbr2fl/wt x CD4-Cre (Control) mice. Proportion of T cells expressing NK1.1 is indicated as the percentage of total T cells.
(C) Flow cytometric analysis of CD4 and CD8 expression on splenic NK1.1+ T cells in Tgfbr2fl/fl x CD4-Cre mice (KO) or littermate control
Tgfbr2fl/wt x CD4-Cre (Control) mice.
(D) Absolute numbers of aGalCer-CD1d-reactive and total splenic NK1.1+ T cells in Tgfbr2fl/fl x CD4-Cre mice (KO) or littermate control Tgfbr2fl/wt
x CD4-Cre (Control) mice. These results are representative of total 5–10 animals per group analyzed in three independent experiments.
(E) Flow cytometric analysis of expression of a panel of NK cell receptors on NK1.1+ or NK1.12CD4+ and CD8+ T cells in Tgfbr2fl/fl x CD4-Cre mice
(KO) or littermate control Tgfbr2fl/wt x CD4-Cre (Control) mice. These results are representative of total 5–10 animals per group analyzed in three
independent experiments.NK1.1+ and NK1.12 CD8+ T cells from 15- to 17-day-old
mutant mice and total CD8+ T cells from Tgfbr2fl/wt x
CD4-Cre littermate controls. The littermate controls
with intact TGF-b signaling had very few NK1.1+ CD8+
T cells, making their analysis all but impossible. In
agreement with flow cytometric analysis, transcriptional
profiling with Affimetrix oligonucleotide arrays revealed
substantial upregulation of characteristic NK cell genes
including the gene that encodes DAP12 (Tyrobp or
Karap) and numerous NK cell receptors (Figure 5).
Another distinguishing feature of NK1.1+CD8+ T cells
program was a marked increase in mRNA encoding
proinflammatory chemokines CCL6 and CCL9 as well
as CCL9 receptor CXCR3 normally associated with the
Th1 type inflammatory response. Increased expression
of CCL6, a major player in tissue remodeling and inflam-
mation responsible for recruitment of macrophages andfor induction of tissue-remodeling metalloproteinases
(Ma et al., 2004), is consistent with the substantially
increased accumulation of inflammatory myeloid cells
induced by NK1.1+ T cells as compared to NK1.12 T
cells, whereas coexpression of CCL9 and CXCR3 may
explain congregation of NK1.1+ T cells in the inflamed
tissue forming large foci of infiltrating cells (Figure 4).
Among gene-expression features shared by NK1.1+
and NK1.12 CD8+ T cells that distinguished both of
these T cell subsets from CD8+ T cells in littermate con-
trol mice was a sharp upregulation of a set of genes re-
sponsible for CD8+ T cell and NK cell effector function in-
cluding FasL, IFN-g, perforin, and granzymes A, B, and
K. Consistent with an increase in IFN-g, Tbx21 expres-
sion was greatly increased in both NK1.1+ and NK1.12
T cells, whereas Eomes, another principal regulator of
effector differentiation of CD8+ T cells (Pearce et al.,
TGF-b Signaling Ablation in T Cells
447Figure 4. NK1.1+ T Cells Are Highly Patho-
genic
Representative micrographs of H&E-stained
tissue sections from Rag12/2 mice 5 weeks
after adoptive transfer of splenic NK1.1+ or
NK1.12 T cells from Tgfbr2fl/fl x CD4-Cre
(KO) mice or NK1.12 T cells from littermate
controls (Control) (3200). Recipient mice
were injected with 5 3 105 purified NK1.1+
or NK1.12 T cells. The results are representa-
tive of two independent experiments, utilizing
three or more animals per group.2003; Intlekofer et al., 2005), showed only modest upre-
gulation in NK1.12 but not in NK1.1+CD8+ T cells (Fig-
ure 5). Increased expression of IL-18 and IL-21 in these
cells can promote further increase in IFN-g expression
(Strengell et al., 2003).
To test whether an increase in mRNA encoding Th1 or
cytotoxic T cell effector molecules is also manifested
in corresponding changes at the protein level, we mea-
sured production of IFN-g and TNF-a as well as IL-4
and IL-2 by NK1.1+ and NK1.12 CD4+ and CD8+ T cells
isolated from mutant mice. In agreement with the results
of DNA array analysis, w8% ex vivo isolated NK1.12
CD4+ T cell produced proinflammatory cytokines IFN-g
and TNF-a andw20% of NK1.12 CD8+ T cells produced
IFN-g. w25% NK1.1+ CD4+ and w35% NK1.1+ CD8 T
cells produced IFN-g. In addition, a higher amount of
IFN-g production on a per cell basis was observed for
NK1.1+ CD8+ T cells than for NK1.12 CD8+ T cells
(Figure 6A). We have not observed substantial IL-2 pro-
duction by NK1.1+ CD4+ and CD8+ T cells in mutant mice
(data not shown). In addition, we measured serum con-
centrations of TNF-a and found close to background
amounts of serum TNF-a (<10–15 pg/ml). Thus, the ob-
served pathology is unlikely due to a systemic elevation
in TNF-a.
Next, we examined the expression of cytotoxic effec-
tor molecules FasL and granzyme B by NK1.1+ and
NK1.12 T cells subsets in Tgfbr2fl/fl x CD4-Cre mice.
As a control, we used only NK1.12 T cells from
Tgfbr2fl/WT x CD4-Cre littermates because NK1.1+ T
cell subsets expressing noncanonical TCR are very
small in size in these mice. In addition, we assessed sur-
face expression of a classical lysosomal marker LAMP1
as a measure of cytolytic activity (granule release) of
NK1.1+ and NK1.12 T cells. Flow cytometric analysis
revealed a strikingly high level of FasL and greatly in-
creased level of granzyme B expression by TGF-bRII-
deficient CD4 and CD8 T cells (Figure 6B). Increased
surface expression of LAMP1 is consistent with the
elevated cytolytic activity of TGF-bRII-deficient T cells.
Furthermore, in parallel with the increased IFN-g pro-
duction, NK1.1+ CD4 and CD8 T cell populations asa whole exhibit higher levels of expression of these ef-
fector molecules as compared to their NK1.12 counter-
parts. In agreement with these results, both NK1.1+ and
NK1.12 T cells from Tgfbrfl/fl x CD4-Cre mice were capa-
ble of in vitro killing of syngeneic EL-4 target cells, with
NK1.1+ T cells exhibiting more potent cytolytic activity
than NK1.12 T cells (Figure S2).
Ablation of TGF-bRII in Peripheral NK1.12 T Cells
It is possible that pathogenic noncanonical NK1.1+ T
cells originated from pre-existing small thymically gen-
erated NK1.1+ T cell subsets. Alternatively, these cells
may differentiate from ‘‘conventional’’ self-reactive pe-
ripheral NK1.12 T cells in the absence of TGF-b signal-
ing. Lack of appreciable numbers of NK1.1+CD8+ T cells
in the thymus of Tgfbr2fl/fl x CD4-Cre or littermate con-
trol Tgfbr2fl/WT x CD4-Cre mice was in agreement with
the latter scenario (data not shown). To further test this
possibility, we induced deletion of TGF-bRII in sorted
peripheral NK1.12 T cells expressing conditional
Tgfbr2fl/fl allele upon treatment with the membrane-per-
meable recombinant TAT-Cre protein in vitro. To distin-
guish cells that underwent from cells that escaped Cre-
mediated recombination, Tgfbr2fl/fl mice were bred onto
a Cre recombination reporter allele, i.e., YFP flanked by
loxP sites knocked into the ROSA26 locus (Rosa26-
YFPfl/fl) (Srinivas et al., 2001). The resulting Tgfbr2fl/fl x
Rosa26-YFPfl/fl mice were used as donors of peripheral
NK1.12 T cells in these experiments. Flow cytometric
analysis of TAT-Cre-treated cells showed essentially
all YFP+ T cells lost whereas all YFP2 T cells maintained
TGF-bRII expression (Figure 7A). Next, sorted YFP+ and
YFP2 T cells were adoptively transferred into Rag12/2
recipients, and 4 weeks after transfer were analyzed
for cytokine production, FasL expression, and for the
presence of NK1.1+ CD4+ and NK1.1+ CD8+ T cells.
CD4 and CD8 T cells adoptively transferred into lympho-
penic host upon peripheral deletion of TGF-bRII ex-
hibited increased IFN-g production and higher surface
expression of FasL compared to T cells that failed to
delete Tgfbr2fl/flI (Figure 7B). Approximately 5%–10%
of YFP+ with the induced deletion of TGF-bRII acquired
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448Figure 5. Distinct Gene Expression in NK1.1+ and NK1.12 CD8+ T Cells Lacking TGF-bRII
mRNA expression profiles of NK1.1+ and NK1.12 CD8+ T cells from Tgfbr2fl/fl x CD4-Cre (KO) mice were compared to NK1.12 T cells from litter-
mate control Tgfbr2fl/WT x CD4-Cre (Control) mice. The data are shown as the log2 fold change in NK1.1
2 KO T cells over NK1.12 control T cells
(NK1.1+KO/Control) or NK1.1+ KO T cells over NK1.12 Lit T cells (NK1.1+KO/Control). For select indicated groups of genes, the data are shown as
barographs. DNA array analysis was performed with the mouse 430 2.0 Affymetrix microarrays with RNA isolated from FACS-sorted splenic
NK1.1+ and NK1.12 KO CD8+ T cells and NK1.12 control CD8+ T cells. The complete data set was submitted to GEO database (accession
GSE# 4178).NK1.1 expression whereas none of YFP2 T cells did so
(Figure 7C). Thus, differentiation of nonconventional
NK1.1+ CD4+ and NK1.1+ CD8+ T cells from peripheral
NK1.12 T cells is facilitated upon ablation of TGF-b sig-
naling in these cells. In addition, peripheral deletion of
TGF-bRII in T cells also led to pathology induced in recip-
ient mice (data not shown). Together, these results sup-
port the idea of peripheral differentiation of conventional,likely self-reactive NK1.12 T cells into effector NK1.1+ T
cells as well as NK1.12T cells in TGF-bRII-deficient mice.
Discussion
Multiple cell-intrinsic and cell-extrinsic mechanisms
have been implicated in control of T cell reactivity by
studies linking genetic lesions in a particular mechanism
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449Figure 6. Augmented IFN-gProduction and Expression of Cytotoxic Effector Molecules by CD4+ and CD8+ T Cell Subsets in Tgfbr2fl/fl x CD4-Cre
Mice
(A) Flow cytometric analysis of intracellular cytokine production by ex vivo isolated total or NK1.1+ CD4+ or CD8+ T cells from Tgfbr2fl/fl x CD4-Cre
(KO) or littermate control Tgfbr2fl/fl x CD4-Cre (Control) and by NK1.1+ CD4 T cells from KO mice. FACS profiles of cells isolated from individual
mice are shown. Percentages of cell falling within given corresponding quadrants are indicated. These results are representative of three inde-
pendent experiments with three animals per group.
(B) Flow cytometric analysis of intracellular granzyme B expression by, and surface expression of, Lamp1 and FasL on NK1.1+ and NK1.12CD4+
or CD8+ T cell subsets from KO and control mice. The results are representative of three independent experiments utilizing three or more animals
per group.limiting T cell activation with spontaneous autoimmune
lesions. Among the most vital mechanisms preventing
early-onset multiorgan autoimmune pathology are regu-
lation of T cell activation mediated by CTLA-4 and regu-
lation imparted on effector T cells by Foxp3+ Treg cells
as shown by the fact that mice deficient in either
CTLA-4 or Foxp3 develop autoimmune disease resulting
in death at 3–4 weeks of age. Mice lacking TGF-b1 also
exhibit T cell activation and die at approximately the
same age. However, the lethal pathology in Tgfb12/2
mice can be viewed as a compound phenotype resulting
from impaired development and homeostasis of a vari-
ety of different tissues aggravated by exuberant T cellactivation and differentiation into effector T cells. This
latter view was supported by observation of a substan-
tially delayed pathology caused by activated T cells ex-
pressing DN-TGF-bRII (Gorelik and Flavell, 2000; Lucas
et al., 2000).
Our findings indicate that essentially all early-onset,
life-threatening disease previously reported in Tgfb12/2
mice is due to an impaired control of T cell activation
and differentiation, because we observe very similar tis-
sue lesions and arguably even more aggressive disease
progression in Tgfbr2fl/fl x CD4-Cre mice. Although we
have not directly assessed TCR repertoire and specific-
ity of activated T cells in Tgfbr2fl/fl x CD4-Cre mice, naive
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450Figure 7. In Vitro Induced Ablation of TGF-bRII in Peripheral NK1.12 T Cells Facilitates Their Differentiation into IFN-g-Producing and NK1.1-
Expressing T Cells
Flow cytometric analysis of Cre-induced deletion of TGF-bRII in sorted peripheral NK1.12 T cells from Rosa26-YFP fl/fl x Tgfbr2fl/fl mice.
(A) Sorted NK1.12 T cells treated with TAT-Cre protein were cultured overnight and analyzed for YFP and TGF-bRII expression.
(B and C) The resulting YFP+ (TGF-bRII2) and YFP2 (TGF-bRII+) NK1.12 T cells were sorted and adoptively transferred into Rag12/2 mice. 4
weeks after transfer, T cells were isolated and analyzed for cytokine production and surface expression of FasL and NK1.1. Percentages of
cell falling within given corresponding quadrants are indicated.
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451phenotype of TGF-bRII-deficient T cells specific for a de-
fined foreign antigen strongly argues that self-reactive
or environmental antigen-reactive T cells are activated
in the absence of TGF-b signaling.
Numerous studies have shown that in vitro activation
of peripheral CD252CD4+ T cells in the presence of high
amounts of TGF-b1 induced expression of Foxp3, sug-
gesting a major role for TGF-b signaling in T cells in
the conversion of CD252CD4+ T cells to Treg cells
in vivo (Chen et al., 2003; Cobbold et al., 2004; Park
et al., 2004; Fantini et al., 2004). Although presence of
normal thymic and peripheral Foxp3+CD4+ T cell sub-
sets in previously described DN-TGF-bRII transgenic
mice (J.C.M. and A.Y.R., unpublished observations) ar-
gues against this notion, an incomplete block of TGF-b
receptor signaling in these mice makes it an invalid argu-
ment. Our recent analysis of 7- to 10-day-old TGF-b1-
deficient mice also failed to reveal marked changes in
Foxp3+CD25+CD4+ thymocyte subset (Marie et al.,
2005). It was possible, however, that TGF-b supplied
with mother’s milk might be sufficient to support normal
Foxp3 expression in the thymus in Tgfb12/2 neonates
(Letterio et al., 1994). By deleting TGF-bRII specifically
at the DP stage of T cell development, our study ad-
dresses all potential issues with the previous data and
unequivocally proves that TGF-b signaling is not re-
quired for induction of Foxp3 expression in the thymus
and, therefore, for thymic development of Treg cells.
Greatly diminished numbers of peripheral Foxp3+ T
cells in Tgfbr2fl/fl x CD4-Cre mice raised a possibility
that their paucity is responsible for the observed massive
T cell activation. However, mixed bone marrow transfer
experiments utilizing Tgfbr2fl/fl x CD4-Cre and wild-
type mice as BM donors ruled out this possibility by dem-
onstrating complete resistance of TGF-bRII-deficient
T cells to suppression mediated by wild-type Treg cells.
These results are in agreement with the recently demon-
strated inability of Treg cells to suppress responses of
effector T cells expressing DN-TGF-bRII in the settings
of cytolytic response to neo-antigen-expressing tumor
cells and in experimentally induced tissue-specific in-
flammation in the pancreas and colonic tissue (Peng
et al., 2004; Chen et al., 2005; Fahlen et al., 2005). We
extend these observations to spontaneous systemic
multiorgan autoimmune disease and massive activation
of polyclonal T cells inTgfbr2fl/flx CD4-Cre mice. One can
also consider a possibility that proinflammatory environ-
ment in these mice inactivates Treg cells. However, in
mixed BM chimeras, wild-type Treg cells were capable
of controlling wild-type but not TGFbRII-deficient T cells.
An immediate interpretation of our results is that Treg
cell-derived TGF-b mediates suppression and that in
mixed BM chimeras aggressive autoimmunity associ-
ated with the T cell-specific TGF-bRII ablation is due to
an ‘‘indirect’’ deficiency in Treg function. However, in
preliminary studies, we found that mixed BM chimeras
generated upon transfer of Tgfb12/2 and Foxp32 BM
into irradiated Rag12/2 recipients were devoid of overt
T cell activation and lymphoproliferation similarly to
those generated upon transfer of mixed Tgfb1+/+ and
Tgfb12/2 BM cells or Tgfb1+/+ and Foxp32 BM (J.C.M.,
Y. Rubtsov, and A.Y.R., unpublished observations).
Thus, these data strongly argue against the aforemen-
tioned simplistic model by demonstrating that TGF-b1-deficient Treg cells are fully capable of preventing
systemic lymphoproliferation associated with Foxp3 de-
ficiency as previously suggested (Fahlen et al., 2005). In
agreement with this notion, pathology observed in
Foxp32mice and in Tgfbr2fl/fl x CD4-Cre mice is distinct,
further speaking to a cell-intrinsic mechanism of TGF-b-
mediated control of T cell reactivity.
In agreement with the recent work by Karlsson and
colleagues (Leveen et al., 2005), we have not found sub-
stantial changes in development of major CD4+ and
CD8+ thymocyte subsets in Tgfbr2fl/fl x CD4-Cre mice.
Unexpectedly, we observed a complete block in the
thymic development of canonic CD1d-aGalCer-reactive
NKT cells. Thus, TGF-b signaling in T cells plays a critical
role in NKT cell development. Only slightly decreased
expression of CD1d was found on DP thymocytes in
Tgfbr2fl/fl x CD4-Cre mice as compared to Tgfbr2fl/WT x
CD4-Cre mice (data not shown), so the NKT cell devel-
opment defect cannot be simply explained by a lack of
CD1d on selecting cells. Furthermore, there is no obvi-
ous connection between TGF-b signaling deficiency
and other known defects in thymic NKT cell develop-
ment associated with SAP-Fyn deficiency or impaired
NF-kB activation (Nichols et al., 2005; Schmidt-Supprian
et al., 2004). Because Cd1d2/2 and Va142/2 mice with a
complete block in NKT cell development do not exhibit
any signs of unprovoked autoimmunity (Mendiratta
et al., 1997; Cui et al., 1997), we think that it is highly un-
likely that NKT cell deficiency contributes substantially
to the disease observed in Tgfbr2fl/fl x CD4-Cre mice.
Within CD1d-GalCer-independent NK1.1+ T cells
found in liver and spleen of these mice, CD8+ T cells
are most numerous. Flow cytometric and gene expres-
sion analysis of this subset revealed highly elevated
amounts of cytotoxic effector molecules including
FasL, IFN-g, granzymes, and perforin. Furthermore, we
observed a sharp increase in Tbx21 message in TGF-
bRII-deficient T cells in agreement with the previously
proposed role for TGF-b signaling-mediated transcrip-
tional repression in limiting Tbx21 transcription (Gorelik
et al., 2002; Lin et al., 2005). Furthermore, increased
IL-18 message in TGF-bRII-deficient T cells suggest
that this cytokine, in cooperation with IL-12 supplied
by activated accessory cells and IL-2-like cytokine IL-
21, further augment IFN-g and Tbx21 message levels
(Strengell et al., 2003).
It is likely that sharply increased expression of Tbx21 is
largely responsible for transcriptional effector program
in T cells deficient in TGF-b signaling. Recently, Tbx21
was shown to directly bind Ifng, Fasl, Cxcr3, and its
ligand Ccl3 promoters and to activate transcription of
these genes, which we found upregulated in TGF-bRII-
deficient T cells (Lord et al., 2005; Beima et al., 2006). Fur-
thermore, recent analysis of gene expression in CD8 T
cells activated upon CD3 antibody-induced TCR cross-
linking in the presence or absence of recombinant
TGF-b in vitro provided evidence for Smad-ATF1-medi-
ated repression of IFN-gand granzyme B gene transcrip-
tion in T cells (Thomas and Massague, 2005). Thus, our
study and work by others suggest that drastically accel-
erated program of cytolytic/Th1 cell differentiation in
TGF-b-signaling-deficient T cells is likely due to relief
from direct Smad2/3-mediated repression of synthesis
of mRNAs encoding cytolityc and Th1 effector molecules
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genes mediated by Tbx21. Additional changes in expres-
sion of numerous adhesion molecules, chemokine re-
ceptors, and chemokines facilitate accumulation of
these armed effector T cells in and recruitment of non-
lymphoid inflammatory cells to the tissues.
In conclusion, the data reported here demonstrate
that in peripheral T cells, TGF-b signaling is crucial to re-
strain TCR specificity-dependent Th1 and cytotoxic and
NK cell-like differentiation program which, when left
unchecked, leads to rapidly progressing fatal autoim-
munity. Although mechanistic connection between the
TGF-b1-mediated and Foxp3+ Treg cell-mediated con-
trol of self-reactive T cells remains to be elucidated,
our study firmly established a role for TGF-b signaling
in T cells as the distinct, cell-intrinsic mechanism of con-
trol of autoimmunity acting in cooperation with the
Foxp3-mediated cell-extrinsic mechanism of dominant
tolerance.
Experimental Procedures
Mice
CD4-Cre (Lee et al., 2001) and Tgfbr2fl/fl (Leveen et al., 2005) mice
were provided by Chris Wilson (University of Washington) and Ste-
fan Karlsson (Lund University), respectively. R26RYFP (Rosa26-
YFPfl/fl) mice (Srinivas et al., 2001) were provided by Frank Costantini
(Columbia University). Foxp3-GFP knockin mice and TEa TCR trans-
genic mice were described previously (Fontenot et al., 2005; Grubin
et al., 1997). C57BL/6 (B6), Ly5.1-, and Thy1.1-congenic B6 mice as
well as Rag12/2 mice were purchased from the Jackson Laboratory
(Bar Harbor, ME). All mice were maintained in a specific pathogen-
free animal facility at the University of Washington and handled in
accordance with the institutional guidelines.
Cell Isolation and Flow Cytometric Analyses
Cell populations were purified with an AutoMACS magnetic cell
sorter and magnetic beads (Miltenyi Biotec) as described (Marie
et al., 2005) or with a FACSAria fluorescent cell sorter (BD Bio-
sciences, San Jose, CA). Routinely, purity of all cell preparations
was >90%. Hepatic lymphocytes were purified as described (Wherry
et al., 2003).
Flow cytometry analyses were carried out with a FACSCalibur flow
cytometer (BD Biosciences). Anti-mouse, CD4 (L3T4), CD8a (53-6.7),
CD8b (CT-CD8b), CD11a (M17/4), CD11b (M1/70), CD11c (N418),
CD16/32 (24G2), CD19 (MB19-1), CD54 (YN1/1.7.4), CD25 (PC-61),
CD44 (IM7), CD62L (MEL-14), CD69 (H1.2F3), CD90.1 (Thy1.1),
CD94 (18d3), CD95L (MLF3), CD127 (A7R34), CD154 (MR1), DX5
(DX5), LAMP1 (DATK32), NKG2A/C/E (20d5), NKG2D (C7), NK1.1
(NKR-P1C), TCRb (H57-597), Va2 (B20.1), Va3 (RR3-16), Va11
(ARR-81), Vb3 (KJ25), Vb4 (KT4-10), Vb6 (RR4-7), Vb8 (F23.1), Vb10
(B21.5), Vb11 (RR3-15), Vb13 (MR12-5), Vb14 (14-2/a), and anti-gran-
zyme B antibodies were purchased from BD Biosciences and eBio-
science (San Diego, CA), and anti-TGF-bRII and anti-GITR anti-
bodies from R&D Systems (Minneapolis, MN). Antibodies specific
for mouse IL-2 (JES6-5H4), IL-4 (11B11), IFN-g (XMG1.2), and TNF-a
(MP6-XT22) (eBioscience) were used for intracellular cytokine
staining of T cells stimulated with anti-CD3 (2C11, 15 mg/ml) and
monensin (2 mM) for 4 hr according to the manufacturer’s instruction.
PE-labeled aGalCer-CD1d tetramers were provided by Mitch Kro-
nenberg (La Jolla Institute for Allergy and Immunology) and Albert
Bendelac (University of Chicago).
In Vitro Induction of Cre-Mediated Recombination
Recombinant TAT-Cre protein was purified from bacterial lysates as
described (Peitz et al., 2002). T cells from Rosa26-YFP fl/fl x Tgfbr2fl/fl
or Rosa26-YFP fl/fl were incubated with 80 mg/ml of recombinant
TAT-Cre protein in RPMI1640 supplemented with 5% FCS, 200 mM
L-glutamine, 1 mM sodium pyruvate, 10 mM HEPES, and 100 U/ml
penicillin/streptomycin (all from Invitrogen, Carlsbad, CA) for 1 hr at
37C, 5% CO2. After extensive washes, cells were cultured overnightwith T cell-depleted irradiated (1500 rad) splenocytes in supple-
mented RPMI1640. Cre-mediated recombination was assessed by
flow cytometric analysis of YFP expression.
Adoptive T Cell Transfers and Radiation Bone Marrow Chimeras
For adoptive T cell transfers, Rag12/2 recipient mice were injected
i.v. with indicated sorted T cell subsets (53 105 to 23 106 per recip-
ient) and analyzed 3–5 weeks after transfer for T cell phenotype and
for signs of tissue pathology. Radiation bone marrow chimeras were
generated upon transfer of 2–3 3 106 T cell-depleted BM cells into
lethally irradiated Rag12/2 recipients as previously described (Fon-
tenot et al., 2005).
DNA Array Analysis
RNA isolation and gene array analysis was performed with mouse
430 2.0 Affymetrix DNA microarrays as described elsewhere (Fonte-
not et al., 2005). In brief, data analysis was performed with Biocon-
ductor version 1.5 for the statistical software R (http://www.
r-project.org). Expression values were background corrected, nor-
malized, and summarized with default settings ofgcrmabackground
adjustment package for Bioconductor. To select genes affected
by the lack of TGF-b signaling, we have chosen genes by hand cura-
tion from the list of differentially expressed genes with a minimum
average log2 average intensity value of 4 and fold change of 2.
Serum Ig Isotyping, Immunoblot, and Histological
Tissue Analyses
Serum Ig isotypes were quantified by Ig isotype-specific ELISA per-
formed according to the manufacturer’s protocol (SBA Clonotyping
System/HRP, Southern Biotechnology Associates, Inc., Birming-
ham, AL).
Serum IgG autoantibodies were detected with Western blot
analysis of electrophoretically separated detergent (1% NP-40)-
solubilized tissue proteins isolated from indicated organs of Rag12/2
mice. Tissue lysates were normalized for the protein content,
separated in 4%–20% SDS-PAGE gels, and transferred onto the
nitrocellulose membrane. Transferred tissue proteins were probed
with sera (1:250 dilution) isolated from mutant or control mice fol-
lowed by HRP-conjugated sheep anti-mouse IgG (Amersham
Bioscience, UK).
Tissue sections were prepared with 10% buffered formalin fixed,
paraffin-embedded tissues and stained with hematoxylin-eosin
with standard protocol.
In Vitro Cytotoxic T Cell Assay
Cytotoxic activity of splenic T cell subsets from mutant and litter-
mate control mice was assessed with the DNA-fragmentation assay
(JAM test). Effector T cells and 3H-thymidine-labeled EL-4 (H-2b) tar-
get cells were cocultured in 96-well round-bottom plates for 5 hr at
37C, and target cell lysis was assessed as described previously
(Marie et al., 2002). The lysis (%) was calculated with the following
formula: [(spontaneous cpm 2 experimental cpm)/(spontaneous
cpm)] 3 100, where spontaneous cpm represents value obtained
with target cells incubated in the absence of effector cells.
Supplemental Data
Four Supplemental Figures can be found with this article online at
http://www.immunity.com/cgi/content/full/25/3/441/DC1/.
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